Print

Featured Studies Results

Cancer: Pancreatic | Study Type: Treatment

Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)

https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)

Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)

https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy

Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery

Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery

https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery

Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)

Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle

Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)

Treatment
Post-treatment study to monitor for recurrence

Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors

https://www.facingourrisk.org/research-clinical-trials/study/409 /treating-advanced-solid-tumors-with-a-kras-g12c-mutation-using-targeted-therapies-called-rason-inhibitors

Clinicaltrials.gov identifier:
NCT06128551 (https://clinicaltrials.gov/show/NCT06128551)

Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation

Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors

https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer

Clinicaltrials.gov identifier:
NCT06411691 (https://clinicaltrials.gov/show/NCT06411691)

Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation

Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors

Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)

Treatment
Treatment study for people with advanced solid tumors

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2

Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)

Treatment
Phase 1 treatment study for metastatic solid tumors

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

https://www.facingourrisk.org/research-clinical-trials/study/347 /testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT06958328 (https://clinicaltrials.gov/show/NCT06958328)

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs

Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)

Treatment
Treatment study for people with advanced or metastatic solid tumors

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas

Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.